---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059315"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:31:03.305298+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Annovis completes Phase III data unblinding for buntanetap; topline expected June

## Summary
- Unblinding of Phase III study of buntanetap in early Parkinson's disease completed.
- Topline efficacy data expected in June 2024.
- Delay due to PK measurement error resolved; repeated analysis showed correct 33% blank samples.
- Company confident in data integrity and ready for evaluation with FDA.

## SEC filing metadata
- accession: 0001104659-24-059315
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924059315/0001104659-24-059315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924059315/tm2414019d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059315
- JSON: https://secwatch.observer/filing/0001104659-24-059315.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.